Video

What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other molecular alterations might trigger immunotherapy based on NGS-generated markers and drivers agnostic to tumor type?

Name: What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other molecular alterations might trigger immunotherapy based on NGS-generated markers and drivers agnostic to tumor type?
Uploaded: 2017-09-26T00:00:00+00:00
Description: What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other canonical molecular alterations —NTRK and others — do you see on the horizon that might trigger immunotherapy based on NGS-generated markers and drivers agnostic to tumor type?

Published: September 26, 2017

What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other molecular alterations might trigger immunotherapy based on NGS-generated markers and drivers agnostic to tumor type?

What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other canonical molecular alterations —NTRK and others — do you see on the horizon that might trigger immunotherapy based on NGS-generated markers and drivers agnostic to tumor type?

Overview

CLICK HERE FOR CME CREDIT

Created by

Presenter

Jean-Charles Soria, MD

Professor of Medicine and Medical Oncology
South-Paris University
Cancer Specialist
Institut Gustave Roussy (IGR)
Paris, France